Literature DB >> 25104007

Perforin gene mutation in familial haemophagocytic lymphohistiocytosis: the first reported case from Hong Kong.

Grace P K Chiang1, C K Li1, Vincent Lee1, Frankie W T Cheng1, Alex W K Leung1, Shinsaku Imashuku2, Toshihiko Imamura3, Matthew M K Shing1.   

Abstract

Familial haemophagocytic lymphohistiocytosis is a rare but invariably fatal disease without haematopoietic stem cell transplantation. Genetic defect identification is useful for confirming a clinical diagnosis, predicting the risk of future recurrence, and defining haemophagocytic lymphohistiocytosis predisposition in asymptomatic family members. Notably, familial haemophagocytic lymphohistiocytosis type 2 associates with mutations in the perforin gene (PRF1) which is the most frequent subtype of familial haemophagocytic lymphohistiocytosis. Although perforin gene mutations have been described in Asians, they are largely reported from Japan. The case reported here is the first familial haemophagocytic lymphohistiocytosis type 2 patient in Hong Kong with an identified perforin gene mutation.

Entities:  

Keywords:  Lymphohistiocytosis, hemophagocytic; Perforin

Mesh:

Substances:

Year:  2014        PMID: 25104007     DOI: 10.12809/hkmj134041

Source DB:  PubMed          Journal:  Hong Kong Med J        ISSN: 1024-2708            Impact factor:   2.227


  2 in total

1.  Familial Hemophagocytic Lymphohistiocytosis Type 2 in a Korean Infant With Compound Heterozygous PRF1 Defects Involving a PRF1 Mutation, c.1091T>G.

Authors:  Min Sun Kim; Young Uk Cho; Seongsoo Jang; Eul Ju Seo; Ho Joon Im; Chan Jeoung Park
Journal:  Ann Lab Med       Date:  2017-03       Impact factor: 3.464

2.  Neurologic Manifestations as Initial Clinical Presentation of Familial Hemophagocytic Lymphohistiocytosis Type2 Due to PRF1 Mutation in Chinese Pediatric Patients.

Authors:  Wei-Xing Feng; Xin-Ying Yang; Jiu-Wei Li; Shuai Gong; Yun Wu; Wei-Hua Zhang; Tong-Li Han; Xiu-Wei Zhuo; Chang-Hong Ding; Fang Fang
Journal:  Front Genet       Date:  2020-03-04       Impact factor: 4.599

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.